Kintai Therapeutics

11:30 AM - 11:45 AM, Tuesday, June 4, 2019 ・ Theater 2
Founded in 2016 by Flagship Labs, the innovation foundry of Flagship Pioneering, Kintai Therapeutics is uniquely focused on unlocking the power of the enteric signaling network and its signals throughout the body to fight disease and restore the health of patients. The company’s Precision Enteric Medicine™ (PEM™) discovery and therapeutic platform is based on a deep understanding of the interconnected biology of the microbiome, gut immune system, and enteric nervous system. Kintai has pioneered a new frontier in gut science, resulting in a unique understanding of a wealth of new genes, metabolites, and signaling molecules, leveraging these insights to rapidly translate into a highly actionable pipeline. The company’s expertise in chemistry, human biology, experimental medicine, and artificial intelligence represents a biology discovery and therapeutic development engine to rapidly identify and deliver new medicines. Kintai’s approach has delivered a pipeline of 10+ programs
Ticker:
Not Provided.
Exchange:
Not Provided.
Company Type:
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
Ulcerative Colitis
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
President & CEO
Kintai Therapeutics